Industry

CHMP recommends approval of BRUKINSA for the treatment of relapsed or refractory marginal zone lymphoma If approved, BRUKINSA will be the first and only approved Bruton’s Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma in Europe CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused … [Read more…]

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc., a clinical-stage biotechnology company focused on the development of novel cancer interventions, today announced that Chief Medical Officer Kartik Krishnan, MD, PhD, will present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Krishnan … [Read more…]

BOSTON–(BUSINESS WIRE)–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that management will present at a fireside chat and participate in a panel discussion on prescription digital therapeutics at the virtual LifeSci Partners HealthTech Symposium on Tuesday, September 20, 2022. Details are as follows: Format: Presentation and Fireside Chat Time: 9:30 a.m. ET … [Read more…]

Julian Adams, Ph.D., to Retire and Remain on the Board as Planned Succession BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that Abigail “Abbey” L. Jenkins, MS, has joined as President & CEO. Ms. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Markets for Insulin Drug and Delivery Technologies” report has been added to ResearchAndMarkets.com’s offering. The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes the market trends of insulin drug and delivery technologies with data from 2021, estimates from 2022, projections of compound … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Home Medical Equipment: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering. Home medical equipment (HME) is a multibillion-dollar industry. This report is an analytical business tool whose primary purpose is to describe and analyze the dynamics of the global market for home medical equipment. The markets for monitors and sensors … [Read more…]

Study of the Paradise™ Ultrasound Renal Denervation System Shows Significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the endovascular Paradise™ Ultrasound … [Read more…]

In a Sacramento Bee ad set to run Sunday, September 18th, AHF implores California Governor Gavin Newsom to help prevent the interruption of care for over 1,400 AIDS patients in Los Angeles LOS ANGELES–(BUSINESS WIRE)–AHF will run a full-page, full-color advocacy ad in the Sacramento Bee this Sunday, September 18th. The ad, headlined, “Governor Newsom: … [Read more…]

FEops HEARTguide significantly improves efficiency and outcomes of LAAO procedures in the PREDICT-LAA Randomized Clinical Trial GENT, Belgium–(BUSINESS WIRE)–Data from the PREDICT-LAA trial, presented at the Late-Breaking Innovation session at the TCT 2022 convention in Boston shows that Left Atrial Appendage occlusion (LAAO) procedures planned by means of FEops HEARTguideTM result in significantly improved procedural … [Read more…]

BOSTON–(BUSINESS WIRE)–Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventricular (LV) unloading with Impella CP for 30 minutes prior to their percutaneous coronary intervention (PCI) compared to patients who received LV unloading followed by immediate … [Read more…]